Tokyo, Oct 26, 2009 (JCN Newswire) - Eisai Co., Ltd. and TSD Japan, Inc. today announced that they had concluded a license and joint development agreement for the development of denileukin diftitox (generic name) in Japan. Under the terms of the agreement, Eisai shall grant TSD the exclusive right to co-develop the drug in Japan, while Eisai will retain the exclusive right to market the product once marketing authorisation has been granted.
